Shanghai Runda Medical Technology Co., Ltd.
603108.SS · SHH
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 10.49B | 2.93B | 816.37M | 417.75M | 0.72 |
| 2023 FY | 9.15B | 2.42B | 646.80M | 273.30M | 0.47 |
| 2024 FY | 8.31B | 2.10B | 354.06M | 55.28M | 0.09 |
| 2025 FY | 6.98B | 1.39B | -18.99M | -548.39M | -0.91 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 14.52B | 9.51B | 1.01B | 6.86B | 3.89B |
| 2023 FY | 14.31B | 8.86B | 1.07B | 6.85B | 4.28B |
| 2024 FY | 14.31B | 8.70B | 1.21B | 5.89B | 4.35B |
| 2025 FY | 13.42B | 8.58B | 962.93M | 6.96B | 3.74B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -428.86M | -272.12M | -700.98M | -66.07M | -262.83M |
| 2023 FY | 729.72M | -319.88M | 409.84M | -377.52M | 171.00M |
| 2024 FY | 646.95M | -229.16M | 417.78M | -337.34M | 275.72M |
| 2025 FY | 692.30M | -250.48M | 441.82M | -18.11M | -150.46M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 5.86B | 11.72B | — | — | — |
| 2023 FY | 11.63B | 17.41B | — | — | — |
| 2024 FY | 9.78B | 14.46B | — | — | — |
| 2025 FY | 9.02B | 15.02B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 1.81B | 381.34M | -2.38M | -51.39M | -0.09 |
| 2025 Q3 | 1.80B | 406.93M | 39.56M | -42.04M | -0.07 |
| 2025 Q4 | 1.73B | 341.65M | -285.81M | -385.70M | -0.64 |
| 2026 Q1 | 1.51B | 351.07M | 13.62M | -53.56M | -0.09 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 13.79B | 8.41B | 876.04M | 5.56B | 4.22B |
| 2025 Q3 | 13.92B | 8.62B | 978.06M | 6.90B | 4.13B |
| 2025 Q4 | 13.42B | 8.58B | 962.93M | 6.96B | 3.74B |
| 2026 Q1 | 13.09B | 8.36B | 859.98M | 6.90B | 3.68B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 37.13M | -35.93M | 1.19M | -65.26M | -25.67M |
| 2025 Q3 | 296.06M | -77.44M | 218.62M | — | 156.03M |
| 2025 Q4 | 199.14M | -116.35M | 82.79M | -32.04 | -15.13M |
| 2026 Q1 | 46.62M | -39.10M | 7.51M | -51.07M | -102.95M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 10.66B | 15.34B | — | — | — |
| 2025 Q3 | 9.66B | 15.58B | — | — | — |
| 2025 Q4 | 9.02B | 15.02B | — | — | — |
| 2026 Q1 | 7.62B | 13.66B | — | — | — |